AstraZeneca (AZN) announced $15B investment in China through 2030 to expand medicines manufacturing and R&D. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China’s high-quality development and, most importantly, bring next-generation modalities to patients.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target raised to 160 GBp from 145 GBp at Berenberg
- AstraZeneca’s AZD3974 Enters Early Human Testing: What Investors Should Watch
- AstraZeneca’s AZD1163 Clears Early Safety Hurdle: What Phase I Completion Means for Investors
- AstraZeneca initiated with a Buy at Citi
- AstraZeneca Sharpens Andexanet Strategy With New Phase I Dosing Study